Immunic reports Q1 net loss $32.6M; cash $186.6M; Phase 3 MS data by end-2026

IMMUNIC, INC.

• Net loss $32.6M ($1.08/share) vs $25.5M ($2.51/share) YoY; R&D expenses $25.6M.
• Closed $200M private placement (up to $400M) in Feb 2026; cash $186.6M funds into late 2027.
• Appointed Michael Panzara, M.D., as CMO; initiated CEO search with commercial neurology expertise.
• Phase 3 ENSURE RMS top-line data expected by end 2026; NDA submission planned mid-2027.
• Key European patent granted for vidofludimus calcium with potential exclusivity into 2043.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.